The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors

Molecular and Cellular Endocrinology

Volumn 321, Issue 1, 2010, Pages 20-28

  Saji, Motoyasu ^a   Ringel, Matthew D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Akt; Anaplastic thyroid cancer; Cowden's syndrome; Follicular thyroid cancer; Invasion; PIK3CA; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AXITINIB; B RAF KINASE; EVEROLIMUS; HAMARTIN; IMATINIB; LEVOTHYROXINE; MAMMALIAN TARGET OF RAPAMYCIN; MOTESANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN PATCHED; PROTEIN RET; RADIOACTIVE IODINE; SORAFENIB; TRANSCRIPTION FACTOR PAX8; TUBERIN; VASCULOTROPIN RECEPTOR; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; COWDEN SYNDROME; DRUG TARGETING; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; HUMAN; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROIDECTOMY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DISEASE PROGRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PRECANCEROUS CONDITIONS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; THYROID NEOPLASMS;

EID: 77950921126     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.10.016     Document Type: Review

References (160)

1. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 2007, 13:3109-3114.
2. Alessi D.R., Andjelkovic M., Caudwell B., et al. Mechanism of activation of protein kinase b by insulin and igf-1. EMBO J. 1996, 15:6541-6551.
3. Alvarez-Nunez F., Bussaglia E., Mauricio D., et al. Pten promoter methylation in sporadic thyroid carcinomas. Thyroid 2006, 16:17-23.
4. Andjelkovic M., Jakubowicz T., Cron P., et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (rac-pk/pkb) promoted by serum and protein phosphatase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5699-5704.
5. Andjelkovic M., Alessi D.R., Meier R., et al. Role of translocation in the activation and function of protein kinase b. J. Biol. Chem. 1997, 272:31515-31524.
6. Astrinidis A., Henske E.P. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005, 24:7475-7481.
7. Au K.S., Ward C.H., Northrup H. Tuberous sclerosis complex: disease modifiers and treatments. Curr. Opin. Pediatr. 2008, 20:628-633.
8. Bader A.G., Kang S., Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1475-1479.
9. Ball D.W., Jin N., Rosen D.M., et al. Selective growth inhibition in braf mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor azd6244. J. Clin. Endocrinol. Metab. 2007, 92:4712-4718.
10. Basolo F., Molinaro E., Agate L., et al. Ret protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur. J. Endocrinol. 2001, 145:599-604.
11. Bellacosa A., Chan T.O., Ahmed N.N., et al. Akt activation by growth factors is a multiple-step process: the role of the ph domain. Oncogene 1998, 17:313-325.
12. Blanco-Aparicio C., Renner O., Leal J.F., et al. Pten, more than the Akt pathway. Carcinogenesis 2007, 28:1379-1386.
13. Brazil D.P., Yang Z.Z., Hemmings B.A. Advances in protein kinase b signalling: Aktion on multiple fronts. Trends Biochem. Sci. 2004, 29:233-242.
14. Bruni P., Boccia A., Baldassarre G., et al. Pten expression is reduced in a subset of sporadic thyroid carcinomas: evidence that pten-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000, 19:3146-3155.
15. Carpten J.D., Faber A.L., Horn C., et al. A transforming mutation in the pleckstrin homology domain of Akt1 in cancer. Nature 2007, 448:439-444.
16. Cass L.A., Meinkoth J.L. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene 2000, 19:924-932.
17. Chalhoub N., Baker S.J. Pten and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4:127-150.
18. Chen M.L., Xu P.Z., Peng X.D., et al. The deficiency of Akt1 is sufficient to suppress tumor development in pten +/- mice. Genes Dev. 2006, 20:1569-1574.
19. Cheng G.Z., Chan J., Wang Q., et al. Twist transcriptionally up-regulates Akt2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007, 67:1979-1987.
20. Chin Y.R., Toker A. Function of Akt/pkb signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal. 2009, 21:470-476.
21. Cho H., Mu J., Kim J.K., et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (pkb beta). Science 2001, 292:1728-1731.
22. Cho H., Thorvaldsen J.L., Chu Q., et al. Akt1/pkbalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001, 276:38349-38352.
23. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study. J. Clin. Oncol. 2008, 26:4708-4713.
24. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142.
25. Coulonval K., Vandeput F., Stein R.C., et al. Phosphatidylinositol 3-kinase, protein kinase b and ribosomal s6 kinases in the stimulation of thyroid epithelial cell proliferation by camp and growth factors in the presence of insulin. Biochem. J. 2000, 348(Pt 2):351-358.
26. Cully M., You H., Levine A.J., et al. Beyond pten mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
27. Dahia P.L.M., Marsh D.J., Zheng Z., et al. Somatic deletions and mutations in the cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997, 57:4710-4713.
28. Davies M.A., Stemke-Hale K., Tellez C., et al. A novel Akt3 mutation in melanoma tumours and cell lines. Br. J. Cancer 2008, 99:1265-1268.
29. Denley A., Kang S., Karst U., et al. Oncogenic signaling of class i PI3K isoforms. Oncogene 2008, 27:2561-2574.
30. Di Cristofano A., Pesce B., Cordon-Cardo C., et al. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 1998, 19:348-355.
31. Di Cristofano A., Pandolfi P.P. The multiple roles of pten in tumor suppression. Cell 2000, 100:387-390.
32. Di Renzo M.F., Olivero M., Serini G., et al. Overexpression of the c-met/hgf receptor in human thyroid carcinomas derived from the follicular epithelium. J. Endocrinol. Invest. 1995, 18:134-139.
33. Diallo-Krou E., Yu J., Colby L.A., et al. Paired box gene 8-peroxisome proliferator-activated receptor-{gamma} fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 2009.
34. Dillon R.L., Marcotte R., Hennessy B.T., et al. Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 2009, 69:5057-5064.
35. Du K., Herzig S., Kulkarni R.N., et al. Trb3: a tribbles homolog that inhibits Akt/pkb activation by insulin in liver. Science 2003, 300:1574-1577.
36. Dworakowska D., Grossman A.B. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr. Relat. Cancer 2009, 16:45-58.
37. Eng C., Leone G., Orloff M.S., et al. Genomic alterations in tumor stroma. Cancer Res. 2009, 69:6759-6764.
38. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
39. Engelman J.A., Chen L., Tan X., et al. Effective use of PI3K and mek inhibitors to treat mutant kras g12d and pik3ca h1047r murine lung cancers. Nat. Med. 2008, 14:1351-1356.
40. Farrow B., Evers B.M. Activation of ppargamma increases pten expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2003, 301:50-53.
41. Feng J., Park J., Cron P., et al. Identification of a pkb/Akt hydrophobic motif ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 2004, 279:41189-41196.
42. Filippa N., Sable C.L., Hemmings B.A., et al. Effect of phosphoinositide-dependent kinase 1 on protein kinase b translocation and its subsequent activation. Mol. Cell Biol. 2000, 20:5712-5721.
43. Fischer A.H., Bond J.A., Taysavang P., et al. Papillary thyroid carcinoma oncogene (ret/ptc) alters the nuclear envelope and chromatin structure. Am. J. Pathol. 1998, 153:1443-1450.
44. Frisk T., Foukakis T., Dwight T., et al. Silencing of the pten tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 2002, 35:74-80.
45. Furuya F., Hanover J.A., Cheng S.-Y. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone ß receptor. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1780-1785.
46. Furuya F., Lu C., Willingham M.C., et al. Inhibition of phosphatidylinositol 3′ kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28:2451-2458.
47. Gao T., Furnari F., Newton A.C. Phlpp: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005, 18:13-24.
48. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
49. Garcia-Rostan G., Costa A.M., Pereira-Castro I., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005, 65:10199-10207.
50. Garofalo R.S., Orena S.J., Rafidi K., et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/pkb beta. J. Clin. Invest. 2003, 112:197-208.
51. Gimm O., Perren A., Weng L.P., et al. Differential nuclear and cytoplasmic expression of pten in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 2000, 156:1693-1700.
52. Greco A., Pierotti M.A., Bongarzone I., et al. Trk-t1 is a novel oncogene formed by the fusion of tpr and trk genes in human papillary thyroid carcinomas. Oncogene 1992, 7:237-242.
53. Grieco M., Santoro M., Berlingieri M.T., et al. Ptc is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
54. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
55. Guigon C.J., Zhao L., Willingham M.C., et al. Pten deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 2009, 28:509-517.
56. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase ii trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 2008, 26:4714-4719.
57. Gupta S., Ramjaun A.R., Haiko P., et al. Binding of Ras to phosphoinositide 3-kinase p110alpha is required for Ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
58. Gustin J.P., Karakas B., Weiss M.B., et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2835-2840.
59. Halachmi N., Halachmi S., Evron E., et al. Somatic mutations of the pten/mmac1 tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 1998, 23:239-243.
60. Heron-Milhavet L., Franckhauser C., Rana V., et al. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol. Cell. Biol. 2006, 26:8267-8280.
61. Higuchi M., Masuyama N., Fukui Y., et al. Akt mediates rac/cdc42-regulated cell motility in growth factor-stimulated cells and in invasive pten knockout cells. Curr. Biol. 2001, 11:1958-1962.
62. Higuchi M., Onishi K., Kikuchi C., et al. Scaffolding function of pak in the PDK1-Akt pathway. Nat. Cell. Biol. 2008, 10:1356-1364.
63. Hou P., Liu D., Shan Y., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007, 13:1161-1170.
64. Hou P., Ji M., Xing M. Association of pten gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/Akt signaling pathway in thyroid tumors. Cancer 2008, 113:2440-2447.
65. Hutchinson J.N., Jin J., Cardiff R.D., et al. Activation of Akt-1 (pkb-α) can accelerate erbb-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004, 64:3171-3178.
66. Irie H.Y., Pearline R.V., Grueneberg D., et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell. Biol. 2005, 171:1023-1034.
67. Jacinto E., Facchinetti V., Liu D., et al. Sin1/mip1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
68. Jhiang S.M., Sagartz J.E., Tong Q., et al. Targeted expression of the ret/ptc1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378.
69. Jia S., Roberts T.M., Zhao J.J. Should individual PI3 kinase isoforms be targeted in cancer?. Curr. Opin. Cell Biol. 2009, 21:199-208.
70. Jin N., Jiang T., Rosen D.M., et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 2009, 94:4107-4112.
71. Jones P.F., Jakubowicz T., Pitossi F.J., et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:4171-4175.
72. Kaneshige M., Kaneshige K., Zhu X., et al. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:13209-13214.
73. Kawakami Y., Nishimoto H., Kitaura J., et al. Protein kinase c betaii regulates Akt phosphorylation on ser-473 in a cell type- and stimulus-specific fashion. J. Biol. Chem. 2004, 279:47720-47725.
74. Kim C.F., Vasko V.V., Kato Y., et al. Akt activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 2005, 146:4456-4463.
75. Kim D., Kim S., Koh H., et al. Akt/pkb promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001, 15:1953-1962.
76. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase ii trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 2009, 27:1675-1684.
77. Koh H., Lee K.H., Kim D., et al. Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase c-related kinase 2 (prk2) cleavage. J. Biol. Chem. 2000, 275:34451-34458.
78. Kohn A.D., Takeuchi F., Roth R.A. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J. Biol. Chem. 1996, 271:21920-21926.
79. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 2006, 6:292-306.
80. Kroll T.G., Sarraf P., Pecciarini L., et al. Pax8-ppargamma1 fusion oncogene in human thyroid carcinoma. Science 2000, 289:1357-1360.
81. Kurose K., Gilley K., Matsumoto S., et al. Frequent somatic mutations in pten and tp53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 2002, 32:355-357.
82. Larson S.D., Jackson L.N., Riall T.S., et al. Increased incidence of well-differentiated thyroid cancer associated with hashimoto thyroiditis and the role of the PI3K/Akt pathway. J. Am. Coll. Surg. 2007, 204:764-773. discussion 773-775.
83. Leboeuf R., Baumgartner J.E., Benezra M., et al. Brafv600e mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 2008, 93:2194-2201.
84. Lemoine N.R., Mayall E.S., Wyllie F.S., et al. Activated Ras oncogenes in human thyroid cancers. Cancer Res. 1988, 48:4459-4463.
85. Li J., Yen C., Liaw D., et al. Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
86. Liang S., Yang N., Pan Y., et al. Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS One 2009, 4:e4295. 10.1371/journal.pone.0004295.
87. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the pten gene in cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16:64-67.
88. Liu H., Radisky D.C., Nelson C.M., et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for tsc2. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4134-4139.
89. Liu Z., Hou P., Ji M., et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 2008, 93:3106-3116.
90. Lynch D.K., Ellis C.A., Edwards P.A., et al. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase b by an indirect mechanism. Oncogene 1999, 18:8024-8032.
91. Mahmoud I.S., Sughayer M.A., Mohammad H.A., et al. The transforming mutation e17k/Akt1 is not a major event in b-cell-derived lymphoid leukaemias. Br. J. Cancer 2008, 99:488-490.
92. Maira S.M., Galetic I., Brazil D.P., et al. Carboxyl-terminal modulator protein (ctmp), a negative regulator of pkb/Akt and v-Akt at the plasma membrane. Science 2001, 294:374-380.
93. Malanga D., Scrima M., De Marco C., et al. Activating e17k mutation in the gene encoding the protein kinase Akt1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008, 7:665-669.
94. Mani S.A., Guo W., Liao M.-J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
95. Masure S., Haefner B., Wesselink J.J., et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur. J. Biochem. 1999, 265:353-360.
96. Meier C.A., Parkison C., Chen A., et al. Interaction of human β 1 thyroid hormone receptor and its mutants with DNA and retinoid x receptor β. T3 response element-dependent dominant negative potency. J. Clin. Invest. 1993, 92:1986-1993.
97. Mende I., Malstrom S., Tsichlis P.N., et al. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001, 20:4419-4423.
98. Meng F., Henson R., Wehbe-Janek H., et al. Microrna-21 regulates expression of the pten tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
99. Miller K.A., Yeager N., Baker K., et al. Oncogenic kras requires simultaneous PI3K signaling to induce erk activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009, 69:3689-3694.
100. Mirza A.M., Kohn A.D., Roth R.A., et al. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/pkb. Cell Growth Differ. 2000, 11:279-292.
101. Mitsuuchi Y., Johnson S.W., Sonoda G., et al. Identification of a chromosome 3p14.3-21.1 gene, appl, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase Akt2. Oncogene 1999, 18:4891-4898.
102. Miyagi E., Braga-Basaria M., Hardy E., et al. Chronic expression of ret/ptc 3 enhances basal and insulin-stimulated PI3 kinase/Akt signaling and increases irs-2 expression in frtl-5 thyroid cells. Mol. Carcinog. 2004, 41:98-107.
103. Miyakawa M., Tsushima T., Murakami H., et al. Increased expression of phosphorylated p70s6 kinase and Akt in papillary thyroid cancer tissues. Endocr. J. 2003, 50:77-83.
104. Motti M.L., Califano D., Troncone G., et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/Akt pathway: regulation of p27kip1 expression and localization. Am. J. Pathol. 2005, 166:737-749.
105. Murga C., Fukuhara S., Gutkind J.S. A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. J. Biol. Chem. 2000, 275:12069-12073.
106. Nakatani K., Sakaue H., Thompson D.A., et al. Identification of a human Akt3 (protein kinase bg) which contains the regulatory serine phosphorylation site. Biochem. Biophys. Res. Commun. 1999, 257:906-910.
107. Nakatani K., Thompson D.A., Barthel A., et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999, 274:21528-21532.
108. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 2008, 21(Suppl 2):S37-43.
109. Ogino S., Nosho K., Kirkner G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 2009, 27:1477-1484.
110. Paes J.E., Ringel M.D. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol. Metab. Clin. North Am. 2008, 37:375-387.
111. Papewalis C., Wuttke M., Schinner S., et al. Role of the novel mTOR inhibitor rad001 (everolimus) in anaplastic thyroid cancer. Horm. Metab. Res. 2009, 41:752-756.
112. Pekarsky Y., Koval A., Hallas C., et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3028-3033.
113. Pekarsky Y., Hallas C., Croce C.M. The role of tcl1 in human T-cell leukemia. Oncogene 2001, 20:5638-5643.
114. Philp A.J., Campbell I.G., Leet C., et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001, 61:7426-7429.
115. Planchon S.M., Waite K.A., Eng C. The nuclear affairs of pten. J. Cell Sci. 2008, 121:249-253.
116. Podsypanina K., Ellenson L.H., Nemes A., et al. Mutation of pten/mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1563-1568.
117. Powell D.J., Russell J., Nibu K., et al. The ret/ptc3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998, 58:5523-5528.
118. Reddi H.V., McIver B., Grebe S.K.G., et al. The paired box-8/peroxisome proliferator-activated receptor-G oncogene in thyroid tumorigenesis. Endocrinology 2007, 148:932-935.
119. Ricarte-Filho J.C., Ryder M., Chitale D.A., et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for braf, PIK3CA, and Akt1. Cancer Res. 2009, 69:4885-4893.
120. Ringel M.D., Hayre N., Saito J., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001, 61:6105-6111.
121. Saito J., Kohn A.D., Roth R.A., et al. Regulation of frtl-5 thyroid cell growth by phosphatidylinositol (oh) 3 kinase-dependent Akt-mediated signaling. Thyroid 2001, 11:339-351.
122. Saji M., Vasko V., Kada F., et al. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem. Biophys. Res. Commun. 2005, 332:167-173.
123. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
124. Santarpia L., El-Naggar A.K., Cote G.J., et al. Phosphatidylinositol 3-kinase/Akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 2008, 93:278-284.
125. Santoro M., Chiappetta G., Cerrato A., et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the ret/ptc1 oncogene in transgenic mice. Oncogene 1996, 12:1821-1826.
126. Santoro M., Papotti M., Chiappetta G., et al. Ret activation and clinicopathologic features in poorly differentiated thyroid tumors. J. Clin. Endocrinol. Metab. 2002, 87:363-370.
127. Santoro M., Melillo R.M., Fusco A. Ret/ptc activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur. J. Endocrinol. 2006, 155:645-653.
128. Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/pkb by the rictor-mTOR complex. Science 2005, 307:1098-1101.
129. Sato S., Fujita N., Tsuruo T. Modulation of Akt kinase activity by binding to hsp90. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10832-10837.
130. Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 2008, 359:31-42.
131. Sherman S.I. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab. 2009, 94:1493-1499.
132. Shin E., Hong S.W., Kim S.H., et al. Expression of down stream molecules of ret (p-erk, p-p38 mapk, p-jnk and p-Akt) in papillary thyroid carcinomas. Yonsei Med. J. 2004, 45:306-313.
133. Shinohara M., Chung Y.J., Saji M., et al. Akt in thyroid tumorigenesis and progression. Endocrinology 2007, 148:942-947.
134. Staal S.P. Molecular cloning of the Akt oncogene and its human homologues Akt1 and Akt2: amplification of Akt1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:5034-5037.
135. Steck P.A., Pershouse M.A., Jasser S.A., et al. Identification of a candidate tumour suppressor gene, mmac1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
136. Stokoe D. The phosphoinositide 3-kinase pathway and cancer. Expert Rev. Mol. Med. 2005, 7:1-22.
137. Storz P., Toker A. 3′-Phosphoinositide-dependent kinase-1 (PDK-1) in pi 3-kinase signaling. Front. Biosci. 2002, 7:d886-902.
138. Suarez H.G., Du Villard J.A., Caillou B., et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 1988, 2:403-406.
139. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of Akt and eif4e survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
140. Suzuki H., Willingham M.C., Cheng S.Y. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002, 12:963-969.
141. Takano A., Usui I., Haruta T., et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol. Cell. Biol. 2001, 21:5050-5062.
142. Testa J.R., Tsichlis P.N. Akt signaling in normal and malignant cells. Oncogene 2005, 24:7391-7393.
143. Toker A., Newton A.C. Akt/protein kinase b is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 2000, 275:8271-8274.
144. Trimboli A.J., Cantemir-Stone C.Z., Li F., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
145. Trotman L.C., Alimonti A., Scaglioni P.P., et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
146. Vanhaesebroeck B., Ali K., Bilancio A., et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 2005, 30:194-204.
147. Vasko V., Saji M., Hardy E., et al. Akt activation and localization correlate with tumor invasion and oncogene expression in thyroid cancer. J. Mol. Genet. 2004, 41:161-170.
148. Vasko V., Espinosa A.V., Scouten W., et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:2803-2808.
149. Vasudevan K.M., Barbie D.A., Davies M.A., et al. Akt-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
150. Vilgelm A., Lian Z., Wang H., et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in pten+/- mice. Cancer Res. 2006, 66:3375-3380.
151. Vogt P.K., Kang S., Elsliger M.A., et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 2007, 32:342-349.
152. Wang J., Knauf J.A., Basu S., et al. Conditional expression of ret/ptc induces a weak oncogenic drive in thyroid pccl3 cells and inhibits thyrotropin action at multiple levels. Mol. Endocrinol. 2003, 17:1425-1436.
153. Wang Y., Hou P., Yu H., et al. High prevalence and mutual exclusivity of genetic alterations in the PI3K/Akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab. 2007, 92:2387-2390.
154. Wu G., Mambo E., Guo Z., et al. Uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab. 2005, 4688-4693.
155. Wullschleger S., Loewith R., Hall M.N. Tor signaling in growth and metabolism. Cell 2006, 124:471-484.
156. Yeager N., Klein-Szanto A., Kimura S., et al. PTEN loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and cowden disease pathogenesis. Cancer Res. 2007, 67:959-966.
157. Yeager N., Brewer C., Cai K.Q., et al. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-oh initiated proliferative signals in the thyroid follicular epithelium. Cancer Res. 2008, 68:444-449.
158. Yoeli-Lerner M., Yiu G.K., Rabinovitz I., et al. Akt blocks breast cancer cell motility and invasion through the transcription factor nfat. Mol. Cell 2005, 20:539-550.
159. Zhou G.L., Tucker D.F., Bae S.S., et al. Opposing roles for Akt1 and Akt2 in rac/pak signaling and cell migration. J. Biol. Chem. 2006, 281:36443-36453.
160. Zilberman D.E., Cohen Y., Amariglio N., et al. Akt1 e17 k pleckstrin homology domain mutation in urothelial carcinoma. Cancer Genet. Cytogenet. 2009, 191:24-27.